A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD), safety,
pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of E7050 when
administered orally twice daily to patients with advanced solid tumors.